Display options
Cite
Chaparro-Rojas F, Mullane KM. Emerging therapies for Clostridium difficile infection - focus on fidaxomicin. Infect Drug Resist. 2013;6:41-53doi: 10.2147/IDR.S24434.
Chaparro-Rojas, F., & Mullane, K. M. (2013). Emerging therapies for Clostridium difficile infection - focus on fidaxomicin. Infection and drug resistance, 641-53. https://doi.org/10.2147/IDR.S24434
Chaparro-Rojas, Fredy, and Mullane, Kathleen M. "Emerging therapies for Clostridium difficile infection - focus on fidaxomicin." Infection and drug resistance vol. 6 (2013): 41-53. doi: https://doi.org/10.2147/IDR.S24434
Chaparro-Rojas F, Mullane KM. Emerging therapies for Clostridium difficile infection - focus on fidaxomicin. Infect Drug Resist. 2013 Jun 28;6:41-53. doi: 10.2147/IDR.S24434. Print 2013. PMID: 23843696; PMCID: PMC3702225.
Copy Download .nbib Format: NLM
Share it on

Infect Drug Resist. 2013 Jun 28;6:41-53. doi: 10.2147/IDR.S24434. Print 2013.

Emerging therapies for Clostridium difficile infection - focus on fidaxomicin.

Infection and drug resistance

Fredy Chaparro-Rojas, Kathleen M Mullane

Affiliations

  1. Department of Medicine, Section of Infectious Diseases, University of Chicago, Chicago, IL, USA.

PMID: 23843696 PMCID: PMC3702225 DOI: 10.2147/IDR.S24434

Abstract

The epidemiology of Clostridium difficile infections (CDI) has evolved during the last decades, with an increase in the reported incidence, severity of cases, and rate of mortality and relapses. These increases have primarily affected some special populations including the elderly, patients requiring concomitant antibiotic therapy, patients with renal failure, and patients with cancer. Until recently, the treatment of CDI was limited to either metronidazole or vancomycin. New therapeutic options have emerged to address the shortcomings of current antibiotic therapy. Fidaxomicin stands out as the first-in-class oral macrocyclic antibiotic with targeted activity against C. difficile and minimal collateral damage on the normal colonic flora. Fidaxomicin has demonstrated performance not inferior to what is considered the "gold standard" available therapy for CDI, vancomycin, in two separate Phase III clinical trials, but with significant advantages, including fewer recurrences and higher rates of sustained clinical cures. Fidaxomicin constitutes an important development in targeted antibiotic therapy for CDI and must be considered as a first-line agent for patients with risk factors known to portend relapse and severe infection.

Keywords: CDAD; Clostridium difficile infection (CDI); Clostridium difficile-associated diarrhea; fidaxomicin; metronidazole; vancomycin

References

  1. J Antimicrob Chemother. 2011 May;66(5):1096-9 - PubMed
  2. Clin Infect Dis. 2011 Nov;53(10):994-1002 - PubMed
  3. Antimicrob Agents Chemother. 1992 Jun;36(6):1332-5 - PubMed
  4. Clin Infect Dis. 2012 Aug;55 Suppl 2:S162-9 - PubMed
  5. J Antimicrob Chemother. 2005 Oct;56(4):717-25 - PubMed
  6. Gut. 1986 Oct;27(10):1169-72 - PubMed
  7. JAMA. 2012 May 9;307(18):1959-69 - PubMed
  8. Lancet Infect Dis. 2012 Apr;12(4):281-9 - PubMed
  9. Aliment Pharmacol Ther. 2012 Jun;35(12):1355-69 - PubMed
  10. J Antimicrob Chemother. 2004 May;53(5):882-4 - PubMed
  11. Clin Infect Dis. 2012 Aug;55 Suppl 2:S116-20 - PubMed
  12. J Pediatr. 1991 Apr;118(4 Pt 1):633-7 - PubMed
  13. J Antibiot (Tokyo). 1975 Apr;28(4):247-52 - PubMed
  14. Clin Infect Dis. 2012 Aug;55 Suppl 2:S65-70 - PubMed
  15. J Antimicrob Chemother. 2008 Nov;62(5):1046-52 - PubMed
  16. Biomed Pharmacother. 1997;51(2):63-7 - PubMed
  17. J Antibiot (Tokyo). 1975 Jul;28(7):543-9 - PubMed
  18. Clin Infect Dis. 2007 Mar 15;44(6):846-8 - PubMed
  19. Dig Dis Sci. 2011 Jan;56(1):19-26 - PubMed
  20. Ann Pharmacother. 2005 May;39(5):863-8 - PubMed
  21. Clin Microbiol Infect. 2012 Dec;18 Suppl 6:28-35 - PubMed
  22. Arch Intern Med. 1986 Jun;146(6):1101-4 - PubMed
  23. Antimicrob Agents Chemother. 2011 Sep;55(9):4427-9 - PubMed
  24. Clin Infect Dis. 2012 Aug;55 Suppl 2:S93-103 - PubMed
  25. Cochrane Database Syst Rev. 2011 Sep 07;(9):CD004610 - PubMed
  26. Clin Infect Dis. 2012 Aug;55 Suppl 2:S121-6 - PubMed
  27. J Antibiot (Tokyo). 1987 May;40(5):567-74 - PubMed
  28. Chem Biol. 2011 May 27;18(5):580-8 - PubMed
  29. Antimicrob Agents Chemother. 2008 Jul;52(7):2403-6 - PubMed
  30. Am J Infect Control. 1995 Apr;23(2):87-94 - PubMed
  31. Mayo Clin Proc. 2012 Nov;87(11):1106-17 - PubMed
  32. Anaerobe. 2009 Dec;15(6):290-1 - PubMed
  33. Antimicrob Agents Chemother. 2009 Jan;53(1):223-8 - PubMed
  34. Antimicrob Agents Chemother. 2006 Sep;50(9):3028-32 - PubMed
  35. Clin Infect Dis. 2012 Aug;55 Suppl 2:S132-42 - PubMed
  36. Am J Clin Nutr. 1980 Nov;33(11 Suppl):2521-6 - PubMed
  37. Antimicrob Agents Chemother. 2012 Jun;56(6):3448-52 - PubMed
  38. N Engl J Med. 2011 Feb 3;364(5):422-31 - PubMed
  39. Lancet Infect Dis. 2005 Sep;5(9):549-57 - PubMed
  40. J Clin Microbiol. 1982 Jun;15(6):1049-53 - PubMed
  41. J Clin Gastroenterol. 2009 Jan;43(1):91-3 - PubMed
  42. J Antimicrob Chemother. 2004 Jul;54(1):211-6 - PubMed
  43. Expert Rev Anti Infect Ther. 2011 Jul;9(7):767-77 - PubMed
  44. Curr Opin Investig Drugs. 2007 Feb;8(2):168-73 - PubMed
  45. Clin Infect Dis. 2007 Aug 1;45(3):302-7 - PubMed
  46. Antimicrob Agents Chemother. 2011 Nov;55(11):5194-9 - PubMed
  47. Ann Intern Med. 2012 Dec 18;157(12):878-88 - PubMed
  48. J Antimicrob Chemother. 2013 Mar;68(3):515-22 - PubMed
  49. J Infect. 2009 Jun;58(6):403-10 - PubMed
  50. Vaccine. 2012 Jun 19;30(29):4307-9 - PubMed
  51. Nat Rev Microbiol. 2009 Jul;7(7):526-36 - PubMed
  52. Antimicrob Agents Chemother. 2010 May;54(5):2273-5 - PubMed
  53. Org Lett. 2011 Feb 4;13(3):378-81 - PubMed
  54. Clin Microbiol Infect. 2009 Dec;15(12):1067-79 - PubMed
  55. Ann Pharmacother. 2011 Jul;45(7-8):1005-10 - PubMed
  56. Int J Antimicrob Agents. 2009 Mar;33 Suppl 1:S46-50 - PubMed
  57. Clin Infect Dis. 2012 Aug;55 Suppl 2:S154-61 - PubMed
  58. N Engl J Med. 2013 Jan 31;368(5):407-15 - PubMed
  59. J Antibiot (Tokyo). 1975 Apr;28(4):253-9 - PubMed
  60. J Am Geriatr Soc. 2013 Feb;61(2):222-30 - PubMed
  61. Antimicrob Agents Chemother. 2012 Oct;56(10):5023-30 - PubMed
  62. N Engl J Med. 2010 Jan 21;362(3):197-205 - PubMed
  63. Clin Infect Dis. 2008 May 15;46(10):1489-92 - PubMed
  64. J Biol Chem. 2011 Mar 18;286(11):8961-76 - PubMed
  65. Am J Gastroenterol. 2002 Jul;97(7):1769-75 - PubMed
  66. Curr Opin Microbiol. 2011 Oct;14(5):532-43 - PubMed
  67. Toxins (Basel). 2010 Jul;2(7):1848-80 - PubMed
  68. Gastroenterol Clin North Am. 2012 Dec;41(4):763-79 - PubMed
  69. Clin Infect Dis. 2009 Feb 15;48(4):e41-6 - PubMed
  70. Microbiology (Reading). 2010 Nov;156(Pt 11):3354-3359 - PubMed
  71. Clin Infect Dis. 2012 Aug;55 Suppl 2:S71-6 - PubMed
  72. Ther Clin Risk Manag. 2008 Dec;4(6):1343-58 - PubMed
  73. Clin Infect Dis. 2006 Aug 15;43(4):421-7 - PubMed
  74. Infect Control Hosp Epidemiol. 2010 May;31(5):431-55 - PubMed
  75. N Engl J Med. 1994 Jan 27;330(4):257-62 - PubMed
  76. Gastroenterol Res Pract. 2011;2011:106978 - PubMed
  77. Clin Infect Dis. 2011 Sep;53(5):440-7 - PubMed
  78. Am J Infect Control. 2007 Mar;35(2):131-7 - PubMed
  79. J Clin Gastroenterol. 2004 Jul;38(6):475-83 - PubMed
  80. Clin Gastroenterol Hepatol. 2011 Dec;9(12):1044-9 - PubMed
  81. Antimicrob Agents Chemother. 2003 Jul;47(7):2334-8 - PubMed

Publication Types